Liraglutide vs Lixisenatide

Liraglutide (brand names Saxenda and Victoza) and lixisenatide (brand names Adlyxin and Soliqua) are both GLP-1 receptor agonists, a type of medication that mimics a gut hormone to help control blood sugar. Liraglutide is FDA-approved to treat type 2 diabetes, obesity, and reduce cardiovascular risk, while lixisenatide is approved only for type 2 diabetes. Liraglutide is taken as a daily injection, whereas lixisenatide is taken once daily. Liraglutide is made by Novo Nordisk, and lixisenatide is made by Sanofi.

AI summary of the sources below.